Cargando…

1598. Oral Step Down Therapy With Levofloxacin for Low-Risk Febrile Neutropenia in Children

BACKGROUND: Intravenous antibiotic therapy is used for most children with febrile neutropenia (FN). For some children, therapy is completed with outpatient parenteral antibiotic therapy (OPAT). Adult data support step-down therapy to a quinolone-based oral antibiotic regimen for selected patients an...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehra, Sonia, Olson, Jared A, Hersh, Adam L, Thorell, Emily, Lemons, Richard, Pavia, Andrew, Knackstedt, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254444/
http://dx.doi.org/10.1093/ofid/ofy210.1426
_version_ 1783373717258108928
author Mehra, Sonia
Olson, Jared A
Hersh, Adam L
Thorell, Emily
Lemons, Richard
Pavia, Andrew
Knackstedt, Elizabeth
author_facet Mehra, Sonia
Olson, Jared A
Hersh, Adam L
Thorell, Emily
Lemons, Richard
Pavia, Andrew
Knackstedt, Elizabeth
author_sort Mehra, Sonia
collection PubMed
description BACKGROUND: Intravenous antibiotic therapy is used for most children with febrile neutropenia (FN). For some children, therapy is completed with outpatient parenteral antibiotic therapy (OPAT). Adult data support step-down therapy to a quinolone-based oral antibiotic regimen for selected patients and recent pediatric FN guidelines recommend consideration of this strategy, but pediatric data are sparse. Because oral therapy is associated with lower costs and fewer adverse events compared with OPAT, we sought to evaluate the safety and feasibility of an oral step-down program for selected pediatric FN. METHODS: This was a retrospective pre–post study evaluating oral-step down therapy at discharge with levofloxacin for low-risk FN children. Eligibility criteria for oral therapy were: age >1 year, no documented bacteremia, anticipated neutropenia <7 days at discharge, afebrile >24 hours, and were tolerating an enteral diet. Informal discussion began in 2015; the formal practice change was implemented in September 2017. Intervention periods were defined as: pre-intervention (January 2014–March 2015), peri-implementation (March 2015–September 2017); post-intervention (October 2017–March 2018).The primary outcomes were was the percentage of FN patients who were discharged on oral levofloxacin and OPAT during each period. A secondary outcome was the percentage of patients readmitted within 7 days requiring receipt of IV antibiotics. Chi-square tests were used to compare outcomes between periods and statistical process control charts to monitor the changes during the intervention. RESULTS: During the pre-intervention period, 4/107 (3.7%) nonbacteremic FN were discharged on oral levofloxacin. This increased to 62/239 (26%) during the peri-implementation period and 37/68 (54%) during the post-implementation period (P < 0.001) (Figure 1).The percentage of patients discharged on OPAT decreased from 74% in the pre-intervention to 9% in the post-intervention period (P < 0.001). Readmission rates within 7 days of discharge receiving IV antibiotics in the first 24 hours were similar across the study periods (11%, 16%, and 9%, respectively; P = 0.19) (Figure 2). CONCLUSION: An oral step-down program reduced OPAT use for low-risk pediatric FN with no change in readmissions [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6254444
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62544442018-11-28 1598. Oral Step Down Therapy With Levofloxacin for Low-Risk Febrile Neutropenia in Children Mehra, Sonia Olson, Jared A Hersh, Adam L Thorell, Emily Lemons, Richard Pavia, Andrew Knackstedt, Elizabeth Open Forum Infect Dis Abstracts BACKGROUND: Intravenous antibiotic therapy is used for most children with febrile neutropenia (FN). For some children, therapy is completed with outpatient parenteral antibiotic therapy (OPAT). Adult data support step-down therapy to a quinolone-based oral antibiotic regimen for selected patients and recent pediatric FN guidelines recommend consideration of this strategy, but pediatric data are sparse. Because oral therapy is associated with lower costs and fewer adverse events compared with OPAT, we sought to evaluate the safety and feasibility of an oral step-down program for selected pediatric FN. METHODS: This was a retrospective pre–post study evaluating oral-step down therapy at discharge with levofloxacin for low-risk FN children. Eligibility criteria for oral therapy were: age >1 year, no documented bacteremia, anticipated neutropenia <7 days at discharge, afebrile >24 hours, and were tolerating an enteral diet. Informal discussion began in 2015; the formal practice change was implemented in September 2017. Intervention periods were defined as: pre-intervention (January 2014–March 2015), peri-implementation (March 2015–September 2017); post-intervention (October 2017–March 2018).The primary outcomes were was the percentage of FN patients who were discharged on oral levofloxacin and OPAT during each period. A secondary outcome was the percentage of patients readmitted within 7 days requiring receipt of IV antibiotics. Chi-square tests were used to compare outcomes between periods and statistical process control charts to monitor the changes during the intervention. RESULTS: During the pre-intervention period, 4/107 (3.7%) nonbacteremic FN were discharged on oral levofloxacin. This increased to 62/239 (26%) during the peri-implementation period and 37/68 (54%) during the post-implementation period (P < 0.001) (Figure 1).The percentage of patients discharged on OPAT decreased from 74% in the pre-intervention to 9% in the post-intervention period (P < 0.001). Readmission rates within 7 days of discharge receiving IV antibiotics in the first 24 hours were similar across the study periods (11%, 16%, and 9%, respectively; P = 0.19) (Figure 2). CONCLUSION: An oral step-down program reduced OPAT use for low-risk pediatric FN with no change in readmissions [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6254444/ http://dx.doi.org/10.1093/ofid/ofy210.1426 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Mehra, Sonia
Olson, Jared A
Hersh, Adam L
Thorell, Emily
Lemons, Richard
Pavia, Andrew
Knackstedt, Elizabeth
1598. Oral Step Down Therapy With Levofloxacin for Low-Risk Febrile Neutropenia in Children
title 1598. Oral Step Down Therapy With Levofloxacin for Low-Risk Febrile Neutropenia in Children
title_full 1598. Oral Step Down Therapy With Levofloxacin for Low-Risk Febrile Neutropenia in Children
title_fullStr 1598. Oral Step Down Therapy With Levofloxacin for Low-Risk Febrile Neutropenia in Children
title_full_unstemmed 1598. Oral Step Down Therapy With Levofloxacin for Low-Risk Febrile Neutropenia in Children
title_short 1598. Oral Step Down Therapy With Levofloxacin for Low-Risk Febrile Neutropenia in Children
title_sort 1598. oral step down therapy with levofloxacin for low-risk febrile neutropenia in children
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254444/
http://dx.doi.org/10.1093/ofid/ofy210.1426
work_keys_str_mv AT mehrasonia 1598oralstepdowntherapywithlevofloxacinforlowriskfebrileneutropeniainchildren
AT olsonjareda 1598oralstepdowntherapywithlevofloxacinforlowriskfebrileneutropeniainchildren
AT hershadaml 1598oralstepdowntherapywithlevofloxacinforlowriskfebrileneutropeniainchildren
AT thorellemily 1598oralstepdowntherapywithlevofloxacinforlowriskfebrileneutropeniainchildren
AT lemonsrichard 1598oralstepdowntherapywithlevofloxacinforlowriskfebrileneutropeniainchildren
AT paviaandrew 1598oralstepdowntherapywithlevofloxacinforlowriskfebrileneutropeniainchildren
AT knackstedtelizabeth 1598oralstepdowntherapywithlevofloxacinforlowriskfebrileneutropeniainchildren